16 Mar SAHPRA and the Pfizer/Biontech Comirnaty Vaccine
16 March 2021 SAHPRA has approved the Section 21 application for the Pfizer/Biontech Comirnaty Vaccine. Download PDF ...
16 March 2021 SAHPRA has approved the Section 21 application for the Pfizer/Biontech Comirnaty Vaccine. Download PDF ...
12 March 2021 SAHPRA received documentation for the Coronavac vaccine developed by Sinovac on 10 March 2021 SAHPRA will now commence with evaluating the data in assessing the efficacy of the vaccine. Download PDF ...
24 February 2021 SAHPRA has received documentation for the SputnikV vaccine developed by the Gamaleya Institute in Russia on 24 February 2021. SAHPRA will now commence with evaluating the data provided for safety, quality and efficacy of the vaccine. Download PDF ...
18 February 2021 SAHPRA has approved the protocol amendment of the J&J implementation study targeted at Health Care Workers (HCW) for the inclusion of the President and the Deputy President. Whilst they are not classified as HCW, this initiative would assist greatly in encouraging vaccine uptake...
03 February 2021 There is an erroneous notion that SAHPRA “buckled under pressure” as a consequence of the court action brought by, amongst others the Afriforum regarding access to Ivermectin. SAHPRA wishes to state unequivocally that this is NOT the case. The court deliberations of 2 February...
28 January 2021 The second wave of the COVID-19 epidemic in South Africa has put enormous pressure on all aspects of South Africa’s health system and on its communities. SAHPRA appreciates the frustration and pain experienced by healthcare practitioners, patients and families given the limited availability...
27 January 2021 In an effort to enable and support the country’s response in fighting the COVID-19 pandemic, SAHPRA has on 22 January 2021 granted a Section 21 authorisation to the Department of Health for COVISHIELD (a covid-19 vaccine manufactured by Serum Institute of India) for...
06 January 2021 SAHPRA is pleased to announce the commencement of the build of an online directory for over the counter (OTC) SAHPRA approved medicines. This will include all Schedule 0, 1 and 2 registered OTC medicines. A launch date of May 2021 is anticipated. The domain...
15 December 2020 With the advent of COVID-19, vaccine development is a critical area of need. SAHPRA has been proactive and is prepared for the vaccine registration process. The readiness programme includes the establishment of a specialised working group, the COVID-19 Vaccine Registration Working Group (CVr...
10 December 2020 What is a Covid-19 Vaccine? A COVID‑19 vaccine is any of several different vaccine technologies intended to provide immunity against coronavirus disease 2019 (COVID‑19).1 In general, vaccines contain weakened or inactive parts of a particular organism (antigen) that triggers an immune response within the...